你即將離開本站

並前往https://www.hmpgloballearningnetwork.com/site/onc/news/ibrutinib-has-better-outcomes-rituximab-patients-cllsll

Ibrutinib Has Better Outcomes Than Rituximab for Patients ...

This risk is especially important in geographical regions like Asia where many potential therapy recipients have HBV infection.

確定！ 回上一頁

查詢 「ESMO Asia」的人也找了：

  1. esmo asia 2022
    2.
  2. esmo io 2022
    3.
  3. ESMO Asia 2021
    4.
  4. esmo asia 2022 abstract deadline
    5.
  5. ESMO 2021
    6.
  6. esmo asia abstract deadline
    7.
  7. WCLC 2022
    8.
  8. esmo 2022
    9.